open access

Vol 7, No 5 (2011)
Review paper
Published online: 2011-12-09
Get Citation

Ipilimumab — progress in therapy of advanced melanoma

Tomasz Świtaj, Piotr Wysocki, Marek Wojtukiewicz, Piotr Potemski, Lidia Rudnicka, Witold Bartnik, Wojciech Zgliczyński, Piotr Zdunowski, Ewa Kalinka-Warzocha, Ewa Chmielowska, Marek Ziobro, Wojciech Poborski, Emilia Filipczyk-Cisarż, Renata Zaucha, Wojciech Rogowski, Sławomir Falkowski, Kazimierz Drosik, Monika Słowińska, Marek Siemiątkowski, Michał Szkatuła, Cezary Ścibiorski, Andrzej Mackiewicz, Piotr Rutkowski
Onkol. Prak. Klin 2011;7(5):231-245.

open access

Vol 7, No 5 (2011)
REVIEW ARTICLES
Published online: 2011-12-09

Abstract

More than one thousand patients die due to cutaneous melanoma in Poland every year. Apart from high mortality constantly growing incidence with doubling rate in 10 years is also the great concern. Other problems include limited treatment modalities and unsatisfactory results of systemic therapy in advanced melanoma. Activation of antitumor immune response through blockade of CTLA-4 molecule expressed on T cells seems to be a promising treatment for melanoma. Randomized clinical trials showed that administration of anti-CTLA-4 antibodies statistically significantly prolongs overall survival of melanoma patients after failure of previous systemic therapy. Although clinical benefit is limited to minority of patients, this led to the market approval of this drug in US and Europe. Since kinetics of clinical response to ipilimumab is different from standard chemotherapy employment of the immune-related response criteria (modified RECIST criteria) is recommended for evaluation of objective responses to the therapy. The risk of immune related adverse events necessitates careful patient selection and incisive observation during and after ipilimumab treatment. Prompt application of appropriate immunosuppressive and supportive therapy might enable to avoid uncontrolled activation of autoreactive immune response.
Onkol. Prak. Klin. 2011; 7, 5: 231–245

Abstract

More than one thousand patients die due to cutaneous melanoma in Poland every year. Apart from high mortality constantly growing incidence with doubling rate in 10 years is also the great concern. Other problems include limited treatment modalities and unsatisfactory results of systemic therapy in advanced melanoma. Activation of antitumor immune response through blockade of CTLA-4 molecule expressed on T cells seems to be a promising treatment for melanoma. Randomized clinical trials showed that administration of anti-CTLA-4 antibodies statistically significantly prolongs overall survival of melanoma patients after failure of previous systemic therapy. Although clinical benefit is limited to minority of patients, this led to the market approval of this drug in US and Europe. Since kinetics of clinical response to ipilimumab is different from standard chemotherapy employment of the immune-related response criteria (modified RECIST criteria) is recommended for evaluation of objective responses to the therapy. The risk of immune related adverse events necessitates careful patient selection and incisive observation during and after ipilimumab treatment. Prompt application of appropriate immunosuppressive and supportive therapy might enable to avoid uncontrolled activation of autoreactive immune response.
Onkol. Prak. Klin. 2011; 7, 5: 231–245
Get Citation

Keywords

melanoma; ipilimumab; immunotherapy

About this article
Title

Ipilimumab — progress in therapy of advanced melanoma

Journal

Oncology in Clinical Practice

Issue

Vol 7, No 5 (2011)

Article type

Review paper

Pages

231-245

Published online

2011-12-09

Bibliographic record

Onkol. Prak. Klin 2011;7(5):231-245.

Keywords

melanoma
ipilimumab
immunotherapy

Authors

Tomasz Świtaj
Piotr Wysocki
Marek Wojtukiewicz
Piotr Potemski
Lidia Rudnicka
Witold Bartnik
Wojciech Zgliczyński
Piotr Zdunowski
Ewa Kalinka-Warzocha
Ewa Chmielowska
Marek Ziobro
Wojciech Poborski
Emilia Filipczyk-Cisarż
Renata Zaucha
Wojciech Rogowski
Sławomir Falkowski
Kazimierz Drosik
Monika Słowińska
Marek Siemiątkowski
Michał Szkatuła
Cezary Ścibiorski
Andrzej Mackiewicz
Piotr Rutkowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl